ResMed has entered into an Accelerated Share Repurchase (ASR) agreement with Citibank for $450 million of its common stock. This move is part of the company's previously announced $1 billion share repurchase program, signaling a commitment to returning capital to shareholders and potentially boosting earnings per share.
ResMed announced an Accelerated Share Repurchase (ASR) agreement with Citibank for $450 million of its common stock. This ASR is a component of the company's larger, previously authorized $1 billion share repurchase program. Share repurchases typically reduce the number of outstanding shares, which can lead to an increase in earnings per share (EPS) and potentially boost the stock price, making this a positive signal for existing shareholders. In the short term, the market may react favorably to the news of capital return. Long-term implications include improved financial metrics and a potential signal of management's confidence in the company's valuation. For traders, this presents an opportunity to consider the potential for upward price movement due to reduced share count and improved EPS.